Navigation Links
Innovative MIT study estimates extent to which air pollution in China shortens human lives
Date:7/8/2013

CAMBRIDGE, MA -- A high level of air pollution, in the form of particulates produced by burning coal, significantly shortens the lives of people exposed to it, according to a unique new study of China co-authored by an MIT economist.

The research is based on long-term data compiled for the first time, and projects that the 500 million Chinese who live north of the Huai River are set to lose an aggregate 2.5 billion years of life expectancy due to the extensive use of coal to power boilers for heating throughout the region. Using a quasi-experimental method, the researchers found very different life-expectancy figures for an otherwise similar population south of the Huai River, where government policies were less supportive of coal-powered heating.

"We can now say with more confidence that long-run exposure to pollution, especially particulates, has dramatic consequences for life expectancy," says Michael Greenstone, the 3M Professor of Environmental Economics at MIT, who conducted the research with colleagues in China and Israel.

The paper, published today in the Proceedings of the National Academy of Sciences, also contains a generalized metric that can apply to any country's environment: Every additional 100 micrograms of particulate matter per cubic meter in the atmosphere lowers life expectancy at birth by three years.

In China, particulate-matter levels were more than 400 micrograms per cubic meter between 1981 and 2001, according to Chinese government agencies; state media have reported even higher levels recently, with cities including Beijing recording levels of more than 700 micrograms per cubic meter in January. (By comparison, total suspended particulates in the United States were about 45 micrograms per cubic meter in the 1990s.)

Air pollution has become an increasingly charged political issue in China, spurring public protests; last month, China's government announced its intent to adopt a serie
'/>"/>

Contact: Vicki Ekstrom
vekstrom@MIT.EDU
617-253-3411
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. EPA to highlight innovative ways to detect and respond to biological threats
2. Innovative cell printing technologies hold promise for tissue engineering R&D
3. M2SYS Technology Partners with Hitachi to Offer Innovative Biometric Finger Vein Scanner to US Market
4. MedNet Solutions to Demonstrate Its Innovative Suite of eClinical Solutions at the 2012 Bio-IT World Conference & Expo
5. AAPS National Biotechnology Conference to highlight innovative vaccines
6. Summer camp yields innovative apps
7. NIH awards Penn scientists $10 million over 5 years for innovative research on single cells
8. MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech
9. Mussels inspire innovative new adhesive for surgery
10. Innovative uses of nanotechnology in food and agriculture
11. International space station plays host to innovative infectious disease research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... an overview of sales of various drugs used in ... shown in kilograms of active ingredient; antibacterials, anaesthetics, anthelmintics ... are based on sales from wholesalers to pharmacies and ... increase in sales of antibacterials from 2002-2006, sales in ...
... an important signaling molecule in plants - as in ... herb as a model plant, researchers have found that ... in plants. In collaborative work with the research ... doctoral student at the Botany Department, University of Delhi, ...
... has contracted with Florida Tech scientists for a two-year, ... larvae and eggs (ichthyoplankton) that inhabit the St. Johns ... effort to address public concern regarding the cumulative impact ... One measure of the rivers current and ...
Cached Biology News:Nitric oxide regulates plants as well as people 2Grant to fund answers about St. Johns River 2
(Date:12/19/2014)... Dec. 19, 2014 Research and Markets ... of the "Technology Innovations in Smart Fabrics ... http://photos.prnewswire.com/prnh/20130307/600769 ... Fabrics" offers a detailed assessment on technological advancements ... Findings: 1. The Smart Fabrics ...
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 LayerBio ... for ophthalmology and wound care. The National Eye Institute ... awarded LayerBio a Phase I SBIR grant to develop ... Cataracts are the most common cause of vision loss ... of blindness worldwide. According to Dr. Ken Mandell, LayerBio’s ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 iLab Solutions, ... the appointment of Siri Bryant as the new Director ... Director of Core Implementations. These two new leadership positions ... customer service by ensuring that iLab continues to meet ... the last four years, iLab has been deployed at ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 With only ... time special on Sartorius Biohit products . The ... mLINE pipettes, Picus Electronic Pipette Trade-in Program, and free ... and Safety officers around the world. They are ideal ... Other features include:, ,     Full volume range ...
Breaking Biology Technology:Technology Innovations in Smart Fabrics (Technical Insights) 2LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2
... New Findings Also Demonstrate Treatment Results in Improvements in ... Function and Health-Related Quality ... than half of patients,receiving every four week subcutaneous injections ... investigational therapy, experienced sustained,improvements in the joint and skin ...
... Cephalosporin in,Development for Complicated Skin and Skin Structure ... Oct. 27, 2008 Forest,Laboratories, Inc. (NYSE: ... I, a,globally conducted, multi-center, Phase III clinical trial, ... and Chemotherapy /,Infectious Diseases Society of America 46th ...
... 27 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ... Phase 1/2a study,demonstrating that repeat administration with ... improvements in rheumatoid arthritis,(RA) signs and symptoms ... Trubion also announced positive results following preliminary,analyses ...
Cached Biology Technology:One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 2One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 3One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 4One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 5One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 6One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 7One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 8One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 9Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 2Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 3Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 4Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 5Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 6Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 7Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA 8Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rad51, N-terminal...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Biology Products: